10/582640

AP3 Rec'd PCT/PTO 12 JUN 2000 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/US2003/039501

International Filing Date : 12 December 2003 (12.12.2003)

Priority Date(s) Claimed : N/A

Applicant(s) (DO/EO/US) : Alexander MACKERELL, et al.

Title: IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

\boxtimes	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this informatisclosure statement is filed:			
. 0		within three months of the filing date of a national application other than a CPA under § 1.53(d);		
	\boxtimes	within three months of the actual filing date of the national phase of a PCT application; OR		
		before the mailing of a first substantive office action (including after filing of an RCE).		
		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods ed in 37 C.F.R. § 1.97(b), but before the mailing date of:		
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and		

		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a r	notice of allowance under 37 C.F.R. § 1.311;
	AND:	is filed	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Staten	nents U	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited	Materia	<u>ls</u>	
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	\boxtimes	-	s of materials listed but not attached were cited in an international search dated August 5, 2004.
		Not re	quired by 37 CFR § 1.98.
		Copies	s of the materials listed are attached (except for the foregoing).

DOCKET NO.: UNIMD-0011

Non-English	Language References
$\boxtimes_{_{f}}$	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document A = document defining the general state of the art O = non-written disclosure P = intercalated document T = document cited to understand the theory or principle underlying the invention E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date D = cited in the application L = cited for another reason & = publication of member of same patent family
	Translation of other relevant information on foreign search report
Other Inform	<u>ation</u>
	Sees Due (If Any): eck for \$ covering the fee identified above is attached.
Please	e charge to Deposit Account No. 13-3402 \$ for the fee identified above.

DOCKET NO.: UNIMD-0011

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: UNIMD-0011

Date: June 12, 2006

AJZ:ssr

Please type a plus sign (+) inside this box -> +

PTO/SB/08A (0

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known Application Number PCT/US2003/039501 INFORMATION DISCLOSURE 12 December 2003 (12.12.2003) Alexander MACKERELL, et al. STATEMENT BY APPLICANT First Named Inventor Group Art Unit unknown (use as many sheets as necessary) **Examiner Name** unknown Attorney Docket Number **UNIMD-0011** of Sheet

			U.S. P	ATENT DOCUMENTS	
Examiner Initials *	Cite No.1	U.S. Patent Docum	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	001	5,310,760	Α	WASHBURN, ET AL.	05-10-1994
	002	2002/165398	A1	JEPPESEN, ET AL.	11-07-2002
	003	6,114,365	Α	SALOM, ET AL.	09-05-2000
· .	004	6,479,504	B1	MacFARLANE, ET AL.	11-12-2002
	005	6,596,772	B1	HUANG, ET AL.	07-22-2003

	Cite No.1	Foreign Patent Document				Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*		Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)		Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Te.
	006	GB	2 387 172	Α	PANTHERIX LTD	10-08-2003		
	007	wo	00/76982	Α	UNIV IOWA RES FOUND	12-21-2000		004
10.	008	wo	01/83517	Α	TAISHO PHARMA CO LTD, ET AL.	11-08-2001		
	009	wo	01/16097	Α	JALLAL BAHIJA, ET AL.	03-08-2001		005
···								

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.